BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Temozolomide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Temozolomide\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04881032-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT04881032)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: AGuIX Nanopart
 icles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of 
 Newly Diagnosed Glioblastoma\nEstimated primary completion: November 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04881032
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04221035-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Temozolomide: Phase 3 readout est. (NCT04221035)
DESCRIPTION:Temozolomide\, phase 3.\nStudy: High-Risk Neuroblastoma Study 2
  of SIOP-Europa-Neuroblastoma (SIOPEN)\nEstimated primary completion: Nove
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomi
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4221035
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05769660-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Temozolomide: Phase 1 readout est. (NCT05769660)
DESCRIPTION:Temozolomide\, phase 1\, Glioblastoma.\nStudy: A Study to Evalu
 ate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Pat
 ients with Recurrent or Progressive Glioblastoma Multiforme (GBM)\nEstimat
 ed primary completion: 30 November 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05769660
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03011671-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 1 readout est. (NCT03011671)
DESCRIPTION:Temozolomide\, phase 1\, Glioma.\nStudy: Study of Acetazolamide
  With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant G
 lioma\nEstimated primary completion: December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03011671
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04337177-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 1 readout est. (NCT04337177)
DESCRIPTION:Temozolomide\, phase 1.\nStudy: Flavored\, Oral Irinotecan VAL-
 413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediat
 ric Solid Tumors\nEstimated primary completion: December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04337177
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06258018-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT06258018)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: Niraparib and 
 Temozolomide in Patients Glioblastoma\nEstimated primary completion: Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomid
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 258018
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04019262-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT04019262)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: Short Course C
 hemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma\nEst
 imated primary completion: December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04019262
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04478279-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT04478279)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: A Phase 1-2 St
 udy of ST101 in Patients With Advanced Solid Tumors\nEstimated primary com
 pletion: December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04478279
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04211675-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT04211675)
DESCRIPTION:Temozolomide\, phase 1/2.\nStudy: NK Cells Infusions With Irino
 tecan\, Temozolomide\, and Dinutuximab\nEstimated primary completion: Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomi
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4211675
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05664243-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT05664243)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: A Phase 1b / 2
  Drug Resistant Immunotherapy With Activated\, Gene Modified Allogeneic or
  Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolo
 mide in Subjects With Recurrent or Newly Diagnosed Glioblastoma\nEstimated
  primary completion: December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05664243
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07156019-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07156019)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Sintilimab in Combination With 
 Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma\nEst
 imated primary completion: December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07156019
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05661643-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Temozolomide: Phase 2 readout est. (NCT05661643)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: The Efficacy and Safety of Temo
 zolomide in SDH-deficient GIST\nEstimated primary completion: 1 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0566164
 3
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07375563-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Temozolomide: Phase 3 readout est. (NCT07375563)
DESCRIPTION:Temozolomide\, phase 3.\nStudy: Chemoimmunotherapy Combined Wit
 h Autologous NK Cell Therapy for Pediatric Patients With Refractory and Re
 lapsed High-Risk Neuroblastoma and Ganglioneuroblastoma\nEstimated primary
  completion: 15 December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/temozolomide#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07375563
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06475235-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Temozolomide: Phase 1 readout est. (NCT06475235)
DESCRIPTION:Temozolomide\, phase 1.\nStudy: Pembrolizumab + Chemotherapy in
  Newly Diagnosed PCNSL\nEstimated primary completion: 30 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06475235
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03643549-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT03643549)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: Bortezomib and
  Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORT
 EM-17)\nEstimated primary completion: 30 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03643549
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06006273-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 1 readout est. (NCT06006273)
DESCRIPTION:Temozolomide\, phase 1.\nStudy: A Phase Ib Trial of Eribulin in
  Combination With Irinotecan and Temozolamide in Children With Relapsed or
  Refractory Solid Tumors\nEstimated primary completion: 31 December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06006273
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06703255-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT06703255)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioma.\nStudy: A Phase 2 Study of H
 X301 in Patients with High-grade Giloma\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozo
 lomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06703255
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05983237-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT05983237)
DESCRIPTION:Temozolomide\, phase 1/2.\nStudy: Fluzoparib in Combination Wit
 h Camrelizumab and Temozolomide in Advanced Melanoma\nEstimated primary co
 mpletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/temozolomide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05983237
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04901702-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT04901702)
DESCRIPTION:Temozolomide\, phase 1/2.\nStudy: Study of Onivyde With Talazop
 arib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sar
 coma\nEstimated primary completion: 31 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04901702
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06739395-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 2 readout est. (NCT06739395)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Precision Medicine Trial Based 
 on Molecular Matching Therapy for Patients With Standard Treatment Exhaust
 ion\nEstimated primary completion: 31 December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06739395
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06013618-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 2 readout est. (NCT06013618)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Clinical Analysis of Naxitamab 
 (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Ne
 uroblastoma\nEstimated primary completion: 31 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06013618
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04623931-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 2 readout est. (NCT04623931)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Chemotherapy and
  Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histol
 ogical (Molecular) Glioblastomas\nEstimated primary completion: 31 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0462
 3931
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06330337-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 3 readout est. (NCT06330337)
DESCRIPTION:Temozolomide\, phase 3\, Glioma.\nStudy: Effect of Electroacupu
 ncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurre
 nce of High-grade Glioma\nEstimated primary completion: 31 December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06330337
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00978458-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 3 readout est. (NCT00978458)
DESCRIPTION:Temozolomide\, phase 3\, Glioma.\nStudy: Radiation Therapy With
  or Without Temozolomide in Treating Patients With Low-Grade Glioma\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT00978458
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04796012-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT04796012)
DESCRIPTION:Temozolomide\, phase 1/2.\nStudy: VITAS: Atezolizumab in Combin
 ation With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors\nEs
 timated primary completion: January 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04796012
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05188508-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Temozolomide: Phase 2 readout est. (NCT05188508)
DESCRIPTION:Temozolomide\, phase 2\, Glioma.\nStudy: Pembrolizumab\, Olapar
 ib\, and Temozolomide for People With Glioma\nEstimated primary completion
 : January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temoz
 olomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05188508
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03830918-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270103
DTEND;VALUE=DATE:20270104
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT03830918)
DESCRIPTION:Temozolomide\, phase 1/2.\nStudy: Niraparib\, Temozolomide and 
 Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive
 -Stage Small Cell Lung Cancer With a Complete or Partial Response to Plati
 num-Based First-Line Chemotherapy\nEstimated primary completion: 3 January
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03830
 918
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06649851-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Temozolomide: Phase 2 readout est. (NCT06649851)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: G-CSF After Chem
 o-radiation in Patients With Glioblastoma\nEstimated primary completion: 3
 1 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temoz
 olomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06649851
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02287428-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Temozolomide: Phase 1 readout est. (NCT02287428)
DESCRIPTION:Temozolomide\, phase 1\, Glioblastoma.\nStudy: Personalized Neo
 Antigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Dia
 gnosed GBM\nEstimated primary completion: February 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT02287428
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06832267-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270213
DTEND;VALUE=DATE:20270214
SUMMARY:Temozolomide: Phase na readout est. (NCT06832267)
DESCRIPTION:Temozolomide\, phase na.\nStudy: Rituximab-Methotrexate-Temozol
 omide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL\nEstima
 ted primary completion: 13 February 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06832267
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04047706-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:Temozolomide: Phase 1 readout est. (NCT04047706)
DESCRIPTION:Temozolomide\, phase 1\, Glioblastoma.\nStudy: Nivolumab\, BMS-
 986205\, and Radiation Therapy With or Without Temozolomide in Treating Pa
 tients With Newly Diagnosed Glioblastoma\nEstimated primary completion: 15
  February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temoz
 olomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04047706
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01837862-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT01837862)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: A Phase I Stud
 y of Mebendazole for the Treatment of Pediatric Gliomas\nEstimated primary
  completion: March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT01837862
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05691491-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT05691491)
DESCRIPTION:Temozolomide\, phase 1/2.\nStudy: Testing the Combination of th
 e Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Ef
 fectiveness\nEstimated primary completion: 1 March 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05691491
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05030298-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:Temozolomide: Phase 1 readout est. (NCT05030298)
DESCRIPTION:Temozolomide\, phase 1\, Glioma.\nStudy: Preoperative Radiosurg
 ery for the Treatment of High Grade Glioma\, NeoGlioma Trial\nEstimated pr
 imary completion: 15 March 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/temozolomide#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05030298
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05040360-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Temozolomide: Phase 2 readout est. (NCT05040360)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Testing the Use of Chemotherapy
  After Surgery for High-Risk Pancreatic Neuroendocrine Tumors\nEstimated p
 rimary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/temozolomide#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05040360
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03688178-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Temozolomide: Phase 2 readout est. (NCT03688178)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: DC Migration Stu
 dy to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab\
 nEstimated primary completion: 31 March 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03688178
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06827717-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Temozolomide: Phase 2 readout est. (NCT06827717)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Phase II Study of Irinotecan Li
 posome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Meta
 static Ewing Sarcoma\nEstimated primary completion: April 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06827717
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07193654-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07193654)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Stupp Treatment 
 With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spre
 ad\nEstimated primary completion: 1 April 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07193654
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05271240-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Temozolomide: Phase 3 readout est. (NCT05271240)
DESCRIPTION:Temozolomide\, phase 3\, Glioblastoma.\nStudy: Repeated Superse
 lective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozo
 lomide and Radiation Compared to Temozolomide and Radiation Alone in Newly
  Diagnosed GBM\nEstimated primary completion: 1 April 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05271240
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05588453-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT05588453)
DESCRIPTION:Temozolomide\, phase 1/2.\nStudy: Natural Killer Cell Therapy (
 UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melan
 oma Metastatic to the Brain\nEstimated primary completion: 15 April 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05588453
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01864109-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Temozolomide: Phase 2 readout est. (NCT01864109)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Irinotecan and Temozolomide in 
 Combination With Existing High Dose Alkylator Based Chemotherapy for Treat
 ment of Patients With Newly Diagnosed Ewing Sarcoma\nEstimated primary com
 pletion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/te
 mozolomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT01864109
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05999994-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Temozolomide: Phase 2 readout est. (NCT05999994)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: A Master Protocol (LY900023) Th
 at Includes Several Clinical Trials of Drugs for Children and Young Adults
  With Cancer\nEstimated primary completion: May 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05999994
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06850766-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Temozolomide: Phase na readout est. (NCT06850766)
DESCRIPTION:Temozolomide\, phase na\, Glioblastoma.\nStudy: The Feasibility
  and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the T
 reatment of Glioblastoma\nEstimated primary completion: May 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06850766
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07092306-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07092306)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: A Randomized Controlled Study C
 omparing the Safety and Efficacy of Irinotecan Hydrochloride Liposome Inje
 ction Combined With Temozolomide and Vincristine (NALIRI-VT) Versus Irinot
 ecan Combined With Temozolomide and Vincristine (VIT) in Patients With Adv
 anced Ewing's Sarcoma\nEstimated primary completion: 1 May 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07092306
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03189706-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Temozolomide: Phase 1 readout est. (NCT03189706)
DESCRIPTION:Temozolomide\, phase 1.\nStudy: Study of Chemoimmunotherapy for
  High-Risk Neuroblastoma\nEstimated primary completion: June 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT03189706
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03663725-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Temozolomide: Phase 3 readout est. (NCT03663725)
DESCRIPTION:Temozolomide\, phase 3\, Glioblastoma.\nStudy: Treatment Intens
 ification With Temozolomide in Adults With a Glioblastoma\nEstimated prima
 ry completion: June 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT03663725
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03862430-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Temozolomide: Phase 2 readout est. (NCT03862430)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: A Study of NanO2
 ™ Combined With Radiation and Temozolomide in Patients With Newly Diagno
 sed GBM\nEstimated primary completion: 30 June 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03862430
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05698524-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Temozolomide: Phase 1 readout est. (NCT05698524)
DESCRIPTION:Temozolomide\, phase 1\, Glioblastoma.\nStudy: A Study of Temod
 ar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma\nEstima
 ted primary completion: July 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/temozolomide#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05698524
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02649582-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT02649582)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: Adjuvant Dendr
 itic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients\nEstima
 ted primary completion: July 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/temozolomide#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT02649582
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07027748-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Temozolomide: Phase 1 readout est. (NCT07027748)
DESCRIPTION:Temozolomide\, phase 1.\nStudy: Feasibility Study of Prolonged 
 Administration of Naxitamab\, Irinotecan\, and Temozolomide for Patients W
 ith Relapsed or Refractory Neuroblastoma\nEstimated primary completion: 1 
 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomi
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7027748
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01189643-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Temozolomide: Phase 1 readout est. (NCT01189643)
DESCRIPTION:Temozolomide\, phase 1.\nStudy: Irinotecan\, Temozolomide and B
 evacizumab in Combination With Existing High Dose Alkylator Based Chemothe
 rapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Rou
 nd Cell Tumor\nEstimated primary completion: August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT01189643
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05739942-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Temozolomide: Phase 1 readout est. (NCT05739942)
DESCRIPTION:Temozolomide\, phase 1\, Glioblastoma.\nStudy: Dose Finding Stu
 dy of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glio
 blastoma\nEstimated primary completion: 10 August 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05739942
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03122197-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Temozolomide: Phase 1 readout est. (NCT03122197)
DESCRIPTION:Temozolomide\, phase 1\, Glioma.\nStudy: Study of Letrozole in 
 Recurrent Gliomas\nEstimated primary completion: 1 September 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT03122197
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07191431-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270902
DTEND;VALUE=DATE:20270903
SUMMARY:Temozolomide: Phase na readout est. (NCT07191431)
DESCRIPTION:Temozolomide\, phase na.\nStudy: A Clinical Study on the Effica
 cy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or T
 emozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Re
 fractory Primary or Secondary Central Nervous System Lymphoma（SELINA）\
 nEstimated primary completion: 2 September 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07191431
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06038461-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT06038461)
DESCRIPTION:Temozolomide\, phase 1/2.\nStudy: An Open\, Single-center Clini
 cal Study of Surufatinib Combined With Temozolomide and S-1 in the First-l
 ine Treatment of Advanced Neuroendocrine Tumors\nEstimated primary complet
 ion: 15 September 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06038461
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04116411-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270916
DTEND;VALUE=DATE:20270917
SUMMARY:Temozolomide: Phase 2 readout est. (NCT04116411)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: A Clinical Trial
  Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients\nEstim
 ated primary completion: 16 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04116411
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223034-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Temozolomide: Phase 1 readout est. (NCT07223034)
DESCRIPTION:Temozolomide\, phase 1\, Glioblastoma.\nStudy: A Study of 177Lu
 -PSMA-617 in People With Gliomas\nEstimated primary completion: October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07223034
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07476794-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07476794)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Daily Temozolomi
 de for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed G
 liOblatoma\nEstimated primary completion: October 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07476794
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06617923-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Temozolomide: Phase 2 readout est. (NCT06617923)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Study of Senaparib in Combinati
 on With Temozolomide in ARID1A Mutation Associated Ovarian Cancer\nEstimat
 ed primary completion: October 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06617923
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05247905-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Temozolomide: Phase 2 readout est. (NCT05247905)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Comparing Capecitabine and Temo
 zolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advan
 ced Pancreatic Neuroendocrine Tumors\, the ComPareNET Trial\nEstimated pri
 mary completion: 1 October 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/temozolomide#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05247905
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03672773-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Temozolomide: Phase 2 readout est. (NCT03672773)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Talazoparib and Low-Dose Temozo
 lomide in Treating Participants With Relapsed or Refractory Extensive-Stag
 e Small Cell Lung Cancer\nEstimated primary completion: 1 October 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT03672773
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05629702-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20271007
DTEND;VALUE=DATE:20271008
SUMMARY:Temozolomide: Phase 2 readout est. (NCT05629702)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: ARISTOCRAT: Blin
 ded Trial of Temozolomide +/- Cannabinoids\nEstimated primary completion: 
 7 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temoz
 olomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05629702
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07599371-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20271010
DTEND;VALUE=DATE:20271011
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07599371)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioma.\nStudy: A Prospective\, Sing
 le-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With
  Temozolomide in the Treatment of Relapsed/Refractory Glioma\nEstimated pr
 imary completion: 10 October 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/temozolomide#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07599371
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06478212-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT06478212)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioma.\nStudy: Vorasidenib in Combi
 nation With Temozolomide (TMZ) in IDH-mutant Glioma\nEstimated primary com
 pletion: November 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06478212
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06297512-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20271109
DTEND;VALUE=DATE:20271110
SUMMARY:Temozolomide: Phase 2 readout est. (NCT06297512)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Evaluate the Rol
 e of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM
 ).\nEstimated primary completion: 9 November 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06297512
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06072586-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Temozolomide: Phase 1 readout est. (NCT06072586)
DESCRIPTION:Temozolomide\, phase 1\, Glioblastoma.\nStudy: A Phase 0/1 Stud
 y of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed G
 lioblastoma (nGBM) Participants With EGFR Alterations or Fusions\nEstimate
 d primary completion: December 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06072586
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225621-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07225621)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Adjuvant Temozol
 omide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodyna
 mic Therapy System for Newly Diagnosed Glioblastoma\nEstimated primary com
 pletion: December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07225621
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444918-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07444918)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Liposomal Irinotecan\, Vincrist
 ine\, Temozolomide\, and Anlotinib for R/R Pediatric Solid Tumors\nEstimat
 ed primary completion: 1 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07444918
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07670026-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07670026)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Intensified Adju
 vant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Rese
 ction or Short-Term Progression\nEstimated primary completion: 1 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076700
 26
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06202066-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Temozolomide: Phase 2 readout est. (NCT06202066)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Temozolomide and Survivin Long 
 Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing M
 etastatic Neuroendocrine Carcinomas\nEstimated primary completion: 15 Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomi
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6202066
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04919382-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Temozolomide: Phase 2 readout est. (NCT04919382)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Temozolomide and Atezolizumab f
 or Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell
  Lung Cancer\nEstimated primary completion: 30 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04919382
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04555577-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Temozolomide: Phase 1 readout est. (NCT04555577)
DESCRIPTION:Temozolomide\, phase 1\, Glioblastoma.\nStudy: Phase I Trial of
  DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant
  Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblast
 oma\nEstimated primary completion: 31 December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04555577
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03491683-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT03491683)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: INO-5401 and I
 NO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (
 REGN2810) in Newly-Diagnosed Glioblastoma (GBM)\nEstimated primary complet
 ion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03491683
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04566380-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Temozolomide: Phase 2 readout est. (NCT04566380)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: ONO-4538 Phase II Rollover Stud
 y (ONO-4538-98)\nEstimated primary completion: 31 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04566380
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07353073-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07353073)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: A Prospective\, Single-Arm\, Ph
 ase II Clinical Study of Neoadjuvant Therapy With Pucotenlimab\, Lenvatini
 b\, and Temozolomide for Resectable Head and Neck Mucosal Melanoma (PLT-NA
 T-HNMM-II)\nEstimated primary completion: 31 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07353073
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02344355-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Temozolomide: Phase 2 readout est. (NCT02344355)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: A Phase 2 Trial 
 of High-Dose Ascorbate in Glioblastoma Multiforme\nEstimated primary compl
 etion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT02344355
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05083754-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Temozolomide: Phase 1 readout est. (NCT05083754)
DESCRIPTION:Temozolomide\, phase 1\, Glioblastoma.\nStudy: Carmustine Wafer
  in Combination With Retifanlimab and Radiation With/Without Temozolomide 
 in Subjects With Glioblastoma\nEstimated primary completion: January 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05083754
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297212-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07297212)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: A Clinical Trial
  Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How
  Well it Works in Patients With Recurrent Glioblastoma\nEstimated primary 
 completion: January 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07297212
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07707973-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280103
DTEND;VALUE=DATE:20280104
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07707973)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Nimotuzumab Comb
 ined With the Stupp Regimen for Postoperative Residual Glioblastoma\nEstim
 ated primary completion: 3 January 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07707973
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07015242-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280109
DTEND;VALUE=DATE:20280110
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07015242)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: A Study of the Efficacy and Saf
 ety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults
  With Transplant-Ineligible Primary Central Nervous System Lymphoma\nEstim
 ated primary completion: 9 January 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07015242
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06504381-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT06504381)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: DB107-RRV\, DB
 107-FC\, and Radiation Therapy With or Without Temozolomide (TMZ) for High
  Grade Glioma\nEstimated primary completion: 31 January 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06504381
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07457775-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07457775)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Liposomal Irinotecan in Combina
 tion With Temozolomide and Bevacizumab in Patients With Advanced STS\nEsti
 mated primary completion: 31 January 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07457775
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07085338-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07085338)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: A Phase II Study With a Safety 
 Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the T
 reatment of Patients With Relapsed or Refractory Neuroblastoma\nEstimated 
 primary completion: 1 February 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07085338
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05417594-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280207
DTEND;VALUE=DATE:20280208
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT05417594)
DESCRIPTION:Temozolomide\, phase 1/2.\nStudy: Study of AZD9574 as Monothera
 py and in Combination With Anti-cancer Agents in Participants With Advance
 d Solid Malignancies\nEstimated primary completion: 7 February 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05417594
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05106296-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Temozolomide: Phase 1 readout est. (NCT05106296)
DESCRIPTION:Temozolomide\, phase 1\, Glioblastoma.\nStudy: Chemo-immunother
 apy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cance
 r\nEstimated primary completion: 30 March 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05106296
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06934889-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Temozolomide: Phase 1 readout est. (NCT06934889)
DESCRIPTION:Temozolomide\, phase 1\, Glioblastoma.\nStudy: Study of ABBV-63
 7 or ABBV-155 With ERAS-801 for People With Glioblastoma\nEstimated primar
 y completion: April 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06934889
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05128734-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Temozolomide: Phase 2 readout est. (NCT05128734)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Temozolomide Monotherapy or in 
 Combination With Olaparib in Patients With Triple Negative Breast Cancer (
 TNBC)\nEstimated primary completion: 1 April 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05128734
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05384821-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT05384821)
DESCRIPTION:Temozolomide\, phase 1/2.\nStudy: Metronomic Chemotherapy in Wi
 lms Tumor (MetroWilms-1906)\nEstimated primary completion: May 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05384821
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04945148-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Temozolomide: Phase 2 readout est. (NCT04945148)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Oxidative Phosph
 orylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy 
 Temozolomide\nEstimated primary completion: May 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04945148
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06012695-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT06012695)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: NBM-BMX Admini
 stered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastom
 a\nEstimated primary completion: 30 May 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06012695
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07457307-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Temozolomide: Phase 1 readout est. (NCT07457307)
DESCRIPTION:Temozolomide\, phase 1\, Glioblastoma.\nStudy: Integrating Biol
 ogy for Safe Intensification of Glioblastoma Hypofractionated Treatment on
  the MR-Linac\nEstimated primary completion: June 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07457307
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03213002-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT03213002)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: Oral Capecitab
 ine and Temozolomide (CAPTEM) for Newly Diagnosed GBM\nEstimated primary c
 ompletion: June 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03213002
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06995872-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Temozolomide: Phase 1 readout est. (NCT06995872)
DESCRIPTION:Temozolomide\, phase 1.\nStudy: Phase I Trial of rhIL-15 Plus D
 inutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With
  Relapsed/Refractory Neuroblastoma\nEstimated primary completion: 1 June 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0699587
 2
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05096481-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Temozolomide: Phase 2 readout est. (NCT05096481)
DESCRIPTION:Temozolomide\, phase 2\, Glioma.\nStudy: PEP-CMV Vaccine Target
 ing CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurr
 ent Medulloblastoma\nEstimated primary completion: 15 June 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05096481
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02494804-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT02494804)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioma.\nStudy: Effect of Cytokine-i
 nduced Killer Cells for Stage I-II Malignant Gliomas\nEstimated primary co
 mpletion: July 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT02494804
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02496988-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Temozolomide: Phase 4 readout est. (NCT02496988)
DESCRIPTION:Temozolomide\, phase 4\, Glioma.\nStudy: Effect of Cytokine-ind
 uced Killer Cells for Advanced Malignant Gliomas\nEstimated primary comple
 tion: July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temo
 zolomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT02496988
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04339036-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Temozolomide: Phase 2 readout est. (NCT04339036)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: CapTemY90 for Grade 2/3 NET Liv
 er Metastases\nEstimated primary completion: 1 July 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04339036
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05004116-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT05004116)
DESCRIPTION:Temozolomide\, phase 1/2.\nStudy: A Study of Repotrectinib in C
 ombination With Chemotherapy in Children and Young Adults With Solid Tumor
  Cancer\nEstimated primary completion: August 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05004116
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492680-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07492680)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: A Study of Navlimetostat (BMS-9
 86504) Monotherapy and in Combination With Other Agents in Participants Wi
 th Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (
 MountainTAP-5)\nEstimated primary completion: 15 August 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07492680
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05765812-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT05765812)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: A Study of Zed
 oresertib (Debio 0123) in Combination With Temozolomide in Adult Participa
 nts With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 
 0123) in Combination With Temozolomide and Radiotherapy in Adult Participa
 nts With Newly Diagnosed Glioblastoma\nEstimated primary completion: Septe
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomi
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5765812
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07439172-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07439172)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Pre-Radiation Ch
 emotherapy for Newly Diagnosed High-Grade Glioma.\nEstimated primary compl
 etion: September 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07439172
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07025226-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Temozolomide: Phase 1 readout est. (NCT07025226)
DESCRIPTION:Temozolomide\, phase 1\, Glioma.\nStudy: Medication Combination
 s of Dasatinib\, Quercetin\, Fisetin\, Temozolomide\, LMP744\, and Autolog
 ous TLPO Vaccine for the Treatment of Previously Treated Glioma With Resid
 ual Disease\nEstimated primary completion: 1 September 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07025226
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07847476-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Temozolomide: Phase na readout est. (NCT07847476)
DESCRIPTION:Temozolomide\, phase na\, Glioma.\nStudy: Flubendazole Added to
  Standard Concurrent Chemoradiotherapy With Temozolomide in Patients With 
 High-Grade Glioma\nEstimated primary completion: 1 October 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07847476
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07326566-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07326566)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Study of Silever
 tinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unme
 thylated MGMT and EGFRvIII\nEstimated primary completion: November 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07326566
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06709495-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT06709495)
DESCRIPTION:Temozolomide\, phase 1/2.\nStudy: Phase 1/2 Trial to Evaluate t
 he Safety and Efficacy of PEEL-224 in Combination With Vincristine and Tem
 ozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarc
 omas\nEstimated primary completion: 1 November 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06709495
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03715933-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Temozolomide: Phase 1 readout est. (NCT03715933)
DESCRIPTION:Temozolomide\, phase 1.\nStudy: Phase 1 Study of INBRX-109 in S
 ubjects With Locally Advanced or Metastatic Solid Tumors Including Sarcoma
 s\nEstimated primary completion: December 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03715933
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03351296-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Temozolomide: Phase 2 readout est. (NCT03351296)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Two Chemotherapy Regimens Plus 
 or Minus Bevacizumab\nEstimated primary completion: December 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT03351296
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06450041-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Temozolomide: Phase 2 readout est. (NCT06450041)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: NANT 2021-01 Phase II STING (Se
 quential Temozolomide\, Irinotecan\, NK Cells and GD2 mAb) Trial\nEstimate
 d primary completion: December 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06450041
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07365280-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20281224
DTEND;VALUE=DATE:20281225
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07365280)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Neoantigen-Pulse
 d Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly D
 iagnosed Glioblastoma\nEstimated primary completion: 24 December 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07365280
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318831-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07318831)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Phase II Study of Chidamide-Din
 utuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastom
 a in Children\nEstimated primary completion: 31 December 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07318831
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05439278-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Temozolomide: Phase 3 readout est. (NCT05439278)
DESCRIPTION:Temozolomide\, phase 3\, Glioblastoma.\nStudy: Conventional Ver
 sus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastom
 a\nEstimated primary completion: 31 December 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05439278
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04199026-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Temozolomide: Phase na readout est. (NCT04199026)
DESCRIPTION:Temozolomide\, phase na.\nStudy: Implantable Microdevice for th
 e Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic
  or Recurrent Sarcoma\nEstimated primary completion: 31 December 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04199026
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01777919-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Temozolomide: Phase 2 readout est. (NCT01777919)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Disulfiram/Coppe
 r Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform\n
 Estimated primary completion: January 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT01777919
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07347210-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07347210)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Evaluation of UC
 PVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvan
 t Therapy in Patients With Unmethylated MGMT Glioblastoma\nEstimated prima
 ry completion: January 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/temozolomide#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07347210
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05236036-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20290103
DTEND;VALUE=DATE:20290104
SUMMARY:Temozolomide: Phase 1 readout est. (NCT05236036)
DESCRIPTION:Temozolomide\, phase 1\, Glioblastoma.\nStudy: Mycophenolate Mo
 fetil in Combination With Standard of Care for the Treatment of Glioblasto
 ma\nEstimated primary completion: 3 January 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05236036
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391215-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20290119
DTEND;VALUE=DATE:20290120
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07391215)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: 5G-PEARL: Paxa
 lisib in Malignant Brain Tumours\nEstimated primary completion: 19 January
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07391
 215
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428045-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Temozolomide: Phase 1 readout est. (NCT06428045)
DESCRIPTION:Temozolomide\, phase 1\, Glioma.\nStudy: STARLITE for Unresecta
 ble High-Grade Gliomas\nEstimated primary completion: 30 April 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06428045
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06528496-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20290722
DTEND;VALUE=DATE:20290723
SUMMARY:Temozolomide: Phase 2 readout est. (NCT06528496)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: N10: A Study of Reduced Chemoth
 erapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neurobl
 astoma\nEstimated primary completion: 22 July 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06528496
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07754734-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07754734)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: STUPP Regimen Wi
 th or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promot
 er Methylation\nEstimated primary completion: 31 July 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07754734
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07758062-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07758062)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Levetiracetam Ex
 tended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma\n
 Estimated primary completion: 1 August 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07758062
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03899155-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20290825
DTEND;VALUE=DATE:20290826
SUMMARY:Temozolomide: Phase 2 readout est. (NCT03899155)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Pan Tumor Rollover Study\nEstim
 ated primary completion: 25 August 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03899155
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05843253-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Temozolomide: Phase 2 readout est. (NCT05843253)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Study of Ribocic
 lib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG\,
  H3G34-mutant\nEstimated primary completion: 31 August 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05843253
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07501104-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07501104)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Neoadjuvant Pucotenlimab Combin
 ed With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Mela
 noma\nEstimated primary completion: 1 September 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07501104
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06630260-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT06630260)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: 5G-RUBY: Avuto
 metinib and Defactinib in Malignant Brain Tumours\nEstimated primary compl
 etion: 30 September 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06630260
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07569042-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07569042)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: A Rollover Stu
 dy of NBM-BMX in Combination With Temozolomide in Patients With Newly Diag
 nosed Glioblastoma\nEstimated primary completion: 30 September 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07569042
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07400302-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07400302)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Sintilimab Combined With Chemot
 herapy for Adjuvant Treatment of Mucosal Melanoma After Surgery\nEstimated
  primary completion: 30 September 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07400302
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07605364-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Temozolomide: Phase 2/3 readout est. (NCT07605364)
DESCRIPTION:Temozolomide\, phase 2/3\, Glioblastoma.\nStudy: Testing the Ad
 dition of an Anti-Cancer Drug\, Mycophenolate Mofetil\, to the Usual Treat
 ment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer\nEstim
 ated primary completion: 30 September 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07605364
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07243470-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07243470)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioma.\nStudy: Combination of Tarla
 tamab and Temozolomide in Patients With Central Nervous System Tumors\nEst
 imated primary completion: October 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07243470
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00887146-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Temozolomide: Phase 3 readout est. (NCT00887146)
DESCRIPTION:Temozolomide\, phase 3\, Glioma.\nStudy: Radiation Therapy With
  Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuv
 ant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Gliom
 a\nEstimated primary completion: 31 October 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT00887146
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06681220-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT06681220)
DESCRIPTION:Temozolomide\, phase 1/2.\nStudy: Biomarker Directed Trial of T
 emozolomide and Stenoparib in Relapsed SCLC\nEstimated primary completion:
  31 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/te
 mozolomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06681220
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06172296-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Temozolomide: Phase 3 readout est. (NCT06172296)
DESCRIPTION:Temozolomide\, phase 3.\nStudy: Dinutuximab With Chemotherapy\,
  Surgery and Stem Cell Transplantation for the Treatment of Children With 
 Newly Diagnosed High Risk Neuroblastoma\nEstimated primary completion: 31 
 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozo
 lomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06172296
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07807878-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07807878)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Trial of Temozolomide in BAP1 M
 utated Patients With Advanced or Metastatic Cutaneous Melanoma\nEstimated 
 primary completion: 1 January 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07807878
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06805305-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Temozolomide: Phase 2 readout est. (NCT06805305)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: DOC1021 Dendriti
 c Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (
 GBM)\nEstimated primary completion: March 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06805305
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07894549-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Temozolomide: Phase na readout est. (NCT07894549)
DESCRIPTION:Temozolomide\, phase na\, Glioblastoma.\nStudy: A Single-Arm\, 
 Open-Label\, Multicenter Clinical Study of Teniposide Combined With Temozo
 lomide for the Treatment of Newly Diagnosed Glioblastoma (nGBM) With MGMT 
 Promotor Region Unmethylated\nEstimated primary completion: March 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07894549
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06721689-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT06721689)
DESCRIPTION:Temozolomide\, phase 1/2.\nStudy: PEEL-224\, Vincristine and Te
 mozolomide in Pediatric Solid Tumors\nEstimated primary completion: April 
 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067216
 89
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01356290-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Temozolomide: Phase 2 readout est. (NCT01356290)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Antiangiogenic Therapy for Chil
 dren With Recurrent Medulloblastoma\, Ependymoma\, ATRT and Rare CNS Tumor
 s\nEstimated primary completion: April 2030. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT01356290
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07859059-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07859059)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: Metronomic Tem
 ozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblas
 toma\nEstimated primary completion: 1 June 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07859059
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07141771-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07141771)
DESCRIPTION:Temozolomide\, phase 1/2.\nStudy: An Umbrella Study of Recurren
 t\, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing\nEsti
 mated primary completion: 30 June 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07141771
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04373785-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20300730
DTEND;VALUE=DATE:20300731
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT04373785)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: NG101m Adjuvan
 t Therapy in Glioblastoma Patients\nEstimated primary completion: 30 July 
 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT043737
 85
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07762716-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07762716)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: Combination Im
 munotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment 
 (Designed and Manufactured Per Patient)\, Chemotherapy and Anti PD-1 Thera
 py\nEstimated primary completion: September 2030. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07762716
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07811297-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20300901
DTEND;VALUE=DATE:20300902
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07811297)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: A Study of Cat
 equentinib Hydrochloride (AL3818) in Endometrial\, LGSOC\, STS or GBM Canc
 ers\nEstimated primary completion: 1 September 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07811297
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06861244-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Temozolomide: Phase 2 readout est. (NCT06861244)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Embryonal Tumor With Multilayer
 ed Rosettes\nEstimated primary completion: 30 September 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06861244
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07194044-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Temozolomide: Phase 1 readout est. (NCT07194044)
DESCRIPTION:Temozolomide\, phase 1.\nStudy: Metastatic Ewing's Trial Testin
 g Schedule Enhancement to Improve Outcomes\nEstimated primary completion: 
 October 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozol
 omide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07194044
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07732413-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20301008
DTEND;VALUE=DATE:20301009
SUMMARY:Temozolomide: Phase 1 readout est. (NCT07732413)
DESCRIPTION:Temozolomide\, phase 1.\nStudy: Trial of NLG802 Indoximod Prodr
 ug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer\
 nEstimated primary completion: 8 October 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07732413
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07873996-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20301015
DTEND;VALUE=DATE:20301016
SUMMARY:Temozolomide: Phase 2/3 readout est. (NCT07873996)
DESCRIPTION:Temozolomide\, phase 2/3\, Glioblastoma.\nStudy: Tris-CAR-T Cel
 l Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma\nEstima
 ted primary completion: 15 October 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07873996
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07562971-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07562971)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioma.\nStudy: Focused Ultrasound B
 lood-Brain Barrier Opening in Pontine Diffuse Midline Glioma to Enhance Te
 mozolomide Therapy: Pilot Feasibility Study (FIDES)\nEstimated primary com
 pletion: November 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07562971
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05685004-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Temozolomide: Phase 2/3 readout est. (NCT05685004)
DESCRIPTION:Temozolomide\, phase 2/3\, Glioblastoma.\nStudy: Study of Neoan
 tigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative G
 lioblastoma Multiforme (GBM)\nEstimated primary completion: November 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05685004
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06541262-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20301101
DTEND;VALUE=DATE:20301102
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT06541262)
DESCRIPTION:Temozolomide\, phase 1/2.\nStudy: Silmitasertib (CX-4945) in Co
 mbination With Chemotherapy for Relapsed Refractory Solid Tumors\nEstimate
 d primary completion: 1 November 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06541262
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06208657-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT06208657)
DESCRIPTION:Temozolomide\, phase 1/2.\nStudy: Optimal Precision TherapIes t
 o CustoMISE Care in Childhood and Adolescent Cancer\nEstimated primary com
 pletion: December 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06208657
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06991101-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Temozolomide: Phase 2 readout est. (NCT06991101)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Ruxolitinib With
  Radiation and Temozolomide Compared to Radiation and Temozolomide for New
 ly Diagnosed Glioblastoma\nEstimated primary completion: December 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06991101
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06942039-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Temozolomide: Phase 1 readout est. (NCT06942039)
DESCRIPTION:Temozolomide\, phase 1.\nStudy: Pilot Study of IT Topotecan and
  Maintenance Chemotherapy for HR-EBTs in Children < 6 Years\, Post Consoli
 dation\nEstimated primary completion: 31 December 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06942039
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07334301-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07334301)
DESCRIPTION:Temozolomide\, phase 1/2.\nStudy: A Multi-Arm\, Platform Trial 
 For Relapsed Neuroblastoma\nEstimated primary completion: 31 December 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07334301
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02813135-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT02813135)
DESCRIPTION:Temozolomide\, phase 1/2.\nStudy: European Proof-of-Concept The
 rapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refrac
 tory Tumors\nEstimated primary completion: February 2031. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT02813135
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07549321-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Temozolomide: Phase 2/3 readout est. (NCT07549321)
DESCRIPTION:Temozolomide\, phase 2/3.\nStudy: A Safety and Efficacy Study o
 f hu14 in High-Risk Neuroblastoma Patients\nEstimated primary completion: 
 March 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolom
 ide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07549321
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07346157-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07346157)
DESCRIPTION:Temozolomide\, phase 1/2.\nStudy: Liothyronine in Combination W
 ith BIT Regimen for Medulloblastoma With or Without Minimal Residual Disea
 se\nEstimated primary completion: 31 March 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07346157
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07910760-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20311011
DTEND;VALUE=DATE:20311012
SUMMARY:Temozolomide: Phase 3 readout est. (NCT07910760)
DESCRIPTION:Temozolomide\, phase 3.\nStudy: TRINITY TRIAL\; Trial Of PRRT P
 lus CAPTEM Vs CAPTEM Alone In Well Differentiated GEP NETS\nEstimated prim
 ary completion: 11 October 2031. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/temozolomide#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07910760
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07932808-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20311126
DTEND;VALUE=DATE:20311127
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07932808)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Naxitamab Enabled Transplant-Fr
 ee Study in High-Risk Neuroblastoma\nEstimated primary completion: 26 Nove
 mber 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomi
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7932808
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04765514-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Temozolomide: Phase 2 readout est. (NCT04765514)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Chemoradiotherap
 y Versus Chemotherapy for Elderly and Frail GBM Patients\nEstimated primar
 y completion: June 2032. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04765514
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389278-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07389278)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: Combination AD
 I-PEG 20\, TMZ\, and RT for Treatment of Newly Diagnosed High-grade Glioma
  (HGG)\nEstimated primary completion: 30 June 2032. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07389278
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06477939-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Temozolomide: Phase 3 readout est. (NCT06477939)
DESCRIPTION:Temozolomide\, phase 3\, Glioblastoma.\nStudy: Study of Adding 
 or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Ra
 diation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Pat
 ients\nEstimated primary completion: 31 December 2032. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06477939
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07888647-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20340201
DTEND;VALUE=DATE:20340202
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07888647)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: IDH1-vac in Patients With Newly
  Diagnosed IDH1R132H-positive High-grade Astrocytomas\nEstimated primary c
 ompletion: 1 February 2034. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/temozolomide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07888647
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06023641-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20341031
DTEND;VALUE=DATE:20341101
SUMMARY:Temozolomide: Phase 2 readout est. (NCT06023641)
DESCRIPTION:Temozolomide\, phase 2.\nStudy: Treatment of Newly Diagnosed Rh
 abdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinoteca
 n Based Therapy in Children With Intermediate and High Risk Disease\nEstim
 ated primary completion: October 2034. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06023641
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07591493-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20350630
DTEND;VALUE=DATE:20350701
SUMMARY:Temozolomide: Phase 3 readout est. (NCT07591493)
DESCRIPTION:Temozolomide\, phase 3.\nStudy: Adjuvant Trial in Pancreatic Ne
 uroendocrine Tumors\nEstimated primary completion: June 2035. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07591493
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07935889-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20351130
DTEND;VALUE=DATE:20351201
SUMMARY:Temozolomide: Phase 3 readout est. (NCT07935889)
DESCRIPTION:Temozolomide\, phase 3\, Glioblastoma.\nStudy: Advanced Imaging
 -Guided Standard Versus Dose-Intensified Radiation Therapy for the Treatme
 nt of Newly Diagnosed Glioblastoma\, SAGA 2.0 Trial\nEstimated primary com
 pletion: 30 November 2035. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07935889
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07708961-8999@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20360831
DTEND;VALUE=DATE:20360901
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07708961)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Temozolomide\, W
 ith or Without WSD0922-FU\, for the Treatment of EGFR-Mutant\, IDH-Wildtyp
 e Glioblastoma\nEstimated primary completion: 31 August 2036. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07708961
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
